Key result
TricValve implantation complicated by device migration is successfully managed in a severe functional TR case.
Why the study?
Treatment options for severe symptomatic tricuspid regurgitation are limited and surgical repair carries high mortality, prompting exploration of transcatheter tricuspid valve therapy.
Case Report (n=1)
This case report demonstrates the successful management of device migration complications following TricValve implantation for severe functional tricuspid regurgitation.
Tricuspid valve disease, particularly tricuspid regurgitation (TR), has been a 'neglected valvulopathy' for many years. In patients with left heart pathologies, chronic pressure overload on the right ventricle causes functional TR and is associated with a poor prognosis.1 Treatment of severe symptomatic TR has usually been restricted to diuretics and mostly remained ineffective.2 Moreover, patients undergoing surgical repair of isolated tricuspid valve disease have the highest mortality of all valves, due to advanced right ventricular dysfunction and coexisting comorbidities.3 Thus, transcatheter tricuspid valve therapy (TTVT) has emerged as a novel strategy for patients with high or prohibitive surgical risk. In this case, we performed bicaval valve implantation using TricValve to reduce caval backflow on a symptomatic patient with severe functional TR and successfully managed device migration complications.
No takes yet. Share an insight, caveat, or question.
Kültürsay et al. (2022) conducted a case report in Severe functional tricuspid regurgitation (n=1). Bicaval valve implantation using TricValve was evaluated on Management of device migration complications. Bicaval valve implantation using TricValve was performed on a patient with severe functional tricuspid regurgitation, with successful management of device migration complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: